Skip to main content
Fig. 4 | Retrovirology

Fig. 4

From: First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses

Fig. 4

Humoral immune responses of SAV001 vaccine. The humoral immune response was evaluated by assessment of antibody titres against p24, p17, gp120, and gp41 by ELISA. Microtiter plates were coated with specific HIV-1 recombinant antigens (p24, p17, gp120, and gp41 derived from HIV-1 IIIB (Immuno Diagnostics, USA) and serial dilutions of subject sera reacted against the specific antigens. The plates were read on the plate reader at 450 nm. Levels of antibodies in subjects from the entry and from week 4 to week 52 after vaccination were analyzed; p24 antibody (a), p17 antibody (b), gp120 antibody (c), and gp41 antibody (d). Numbers in the x-axis represent entry (E) and weeks after vaccination

Back to article page